X

Trial Profile

The efficacy and safety of anlotinib (AL3818) treatment in patients with advanced non-small cell lung cancer in the real world

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

27 Jun 2022 Results assessing efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world, published in the Journal of Cancer Research and Clinical Oncology.
31 Jan 2021 Primary endpoint has not been met. (Progression-free survival (PFS), as per Results presented at the 2020 World Conference on Lung Cancer
31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com